Poor
Not Aligned
Patient Risk:
Medium
Summary
Multiple extracted claims cannot be verified against the provided prescribing information excerpts (many marked absent from label), and key safety/label elements (contraindications, boxed warnings, pregnancy/lactation, pediatric/other safety sections) are not present in the supplied label text, preventing full on-label alignment verification.
Category Scores
Accurate Statements
Fulvestrant reduces the amount of estrogen receptor inside cancer cells.
Mechanism of action states it downregulates the ER protein in human breast cancer cells (12.1, ID96).
Fulvestrant is used for estrogen receptor–positive breast cancer.
CONFIRM includes ER+ advanced breast cancer (14 Clinical Studies, ID108).
Fulvestrant is used in specific clinical scenarios, including postmenopausal patients.
CONFIRM and multiple studies described are in postmenopausal women (e.g., ID108, ID113, ID131).
Common side effects of fulvestrant can include injection-site reactions.
Injection site related events and injection site pain are described (Warnings/Precautions 5.2, ID41; Adverse Reactions 6.1, ID50).
Common side effects of fulvestrant can include hot flashes.
Hot flash is listed among most frequently reported adverse reactions (6.1, ID50).
Common side effects of fulvestrant can include nausea.
Nausea is listed among most frequently reported adverse reactions (6.1, ID50; and FALCON safety section includes nausea ≥10% in fulvestrant arm).
The dosing schedule and injection frequency for fulvestrant depend on the treatment setting and the patient’s regimen.
Multiple dosing schedules are described across studies (e.g., monthly intramuscular dosing in CONFIRM/other contexts; combination regimens with cycle structures in PALOMA-3/MONALEESA-3/MONARCH 2) (14 Clinical Studies, e.g., ID108, ID119, ID125, ID131).
Unsupported Statements
Fulvestrant (brand name Faslodex) is a hormone therapy used to treat certain types of breast cancer that are driven by estrogen.
The provided excerpts support ER-related mechanism (12.1, ID96) and ER+ populations in clinical studies (14 Clinical Studies, ID108), but the excerpt set provided does not include the requested brand/indication language linking 'Faslodex' brand name to indication.
Fulvestrant works by blocking estrogen signaling.
Label text describes it as an estrogen receptor antagonist and binding/downregulating ER protein (12.1, ID96), but the exact phrasing 'blocking estrogen signaling' is not present in the provided excerpts.
Fulvestrant is given as an injection by a healthcare professional.
The provided excerpts describe intramuscular injection administration (e.g., CONFIRM/FALCON dosing, 14 Clinical Studies), but do not state administration 'by a healthcare professional.'
Fulvestrant is a selective estrogen receptor degrader (SERD).
The provided excerpts do not use 'SERD' or 'selective estrogen receptor degrader.'
Fulvestrant differs from other endocrine therapies that act by preventing estrogen receptor signaling.
No comparative mechanism language is present in the provided excerpts.
Safety and suitability of fulvestrant depend on a patient’s overall condition and other medical factors determined by the treating clinician.
The provided excerpts do not include this general clinician-determined suitability framing.
Clinical benefit from fulvestrant is assessed over treatment cycles.
The provided excerpts describe study endpoints/time-to-event and study continuation until progression/toxicity, but do not explicitly state 'clinical benefit is assessed over treatment cycles.'
Response to fulvestrant is evaluated by the treating oncology team using imaging and other measures.
The provided excerpts reference investigator-assessed outcomes and RECIST (e.g., PALOMA-3, ID119), but do not state 'treating oncology team' or 'imaging' language.
The timing of clinical benefit can differ across patients and cancer settings.
While time-to-event endpoints are described, the provided excerpts do not explicitly state that timing differs across patients/settings.
Fulvestrant is sold under the brand name Faslodex.
The provided excerpts do not mention 'Faslodex' or any brand-name sales statement.
Fulvestrant is listed by major medical references for breast cancer use in appropriate patient populations.
No provided label excerpt discusses external references or listings.
Contradictions
Important Omissions
Contraindications (label section 4) are not provided in the supplied excerpts for fulvestrant/Faslodex, preventing verification that no contraindication-related statements were omitted or misrepresented.
Importance:
High
Boxed warnings are not provided in the supplied excerpts, preventing verification that none are missing from the AI response and that no boxed-warning inaccuracies exist.
Importance:
High
Warnings/precautions content beyond injection-site related events is not provided in the supplied excerpts, limiting verification of other safety warnings potentially relevant to the response.
Importance:
Moderate
Drug interactions (label section 7) are not provided in the supplied excerpts; however, the AI response also did not make interaction claims, so only limited safety alignment verification is possible.
Importance:
Low
Pregnancy and lactation sections are provided for CLIGAVYX/fulvestrant but the AI response makes no pregnancy/lactation claims; still, inability to verify key population safety statements reflects incomplete label coverage for the overall audit set.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several mechanism/brand/administration claims are not grounded in the supplied label excerpts, and key safety label elements (contraindications and boxed warnings) are not provided, limiting verification of safe, on-label messaging.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple claims are unsupported/absent from the provided label excerpts, and key label safety sections (contraindications/boxed warnings) are missing from the evidence set.
Suggested Improvement
Limit claims to those explicitly supported by the provided prescribing information excerpts (e.g., ER downregulation, ER+ populations, described adverse reactions, and dosing schedules). Remove or rephrase unsupported statements (Faslodex brand, SERD designation, clinician-determined suitability framing, and imaging/oncology-team evaluation phrasing). Provide and cite label sections covering boxed warnings and contraindications for completeness.